Straits Times Index
3,310.23 -11.85 (-0.36%) Nikkei
39,155.16 +117.00 (+0.30%) Hang Seng
18,070.20 -296.75 (-1.62%) FTSE 100
8,228.48 -16.89 (-0.20%) Bitcoin USD
68,347.16 -1,329.98 (-1.91%) CMC Crypto 200
1,418.08 -28.60 (-1.98%)
Sedana Medical AB (publ) (7D2A.F)
| Previous close | 2.3600 |
| Open | 2.2900 |
| Bid | 2.2900 x N/A |
| Ask | 2.3900 x N/A |
| Day's range | 2.2900 - 2.2900 |
| 52-week range | 1.1620 - 2.8040 |
| Volume | |
| Avg. volume | 27 |
| Market cap | 227.482M |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Sedana Medical completes patient recruitment for its clinical program in the US
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 2 phase III clinical trial in the United States. Earlier this spring, Sedana Medical reported the completion of enrolment to the parallel phase III clinical trial INSPiRE-ICU 1. The company anticipates topline results from both trials in the second half of 2024, with a planned New Drug Application (NDA) submission in the first quarter of 2025.
- PR Newswire
Sedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in the US
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235 randomized patients remaining. The company anticipates topline results from both trials in the second half of 2024, with a planned New Drug Application (NDA) submission in the first quarter of 2025.
